is an american development stage regenerative medicine company founded in 2003 with financing from j j development corporation healthcap and oak investment partners which is headquartered in winston salem north carolina its goals are discovering developing manufacturing and commercializing a range of replacement organs and tissues or neo organs and neo tissues to address unmet medical needs in urologic renal gastrointestinal and vascular diseases and disorders the company creates these human neo organs from a patient s own cells or autologous cells in conjunction with its organ regeneration platform the company declared chapter 7 bankruptcy in december 2014 and it along with its assets and tissue engineering samples have been bought back by its creditors and former executives as of march 2015 the purchase was expedited so that time sensitive research can continue founded in 2003 and formerly headquartered in east norriton pennsylvania before moving to winston salem north carolina in 2012 tengion went public in 2010 after its stock has been approved for listing on the nasdaq through a 26 million ipo to help advance its research and development activities some of the groundbreaking regenerative medicine technologies of dr anthony atala director of the wake forest institute for regenerative